Pharmion’s Vidaza Approved For IV Administration
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Pharmion Vidaza Phase III Shows First Survival Advantage In Patients With High-Risk Myelodysplastic Syndromes
Treatment with Vidaza is associated with 24.4-month median survival compared to 15 months for conventional care.
Pharmion Vidaza Phase III Shows First Survival Advantage In Patients With High-Risk Myelodysplastic Syndromes
Treatment with Vidaza is associated with 24.4-month median survival compared to 15 months for conventional care.
Vidaza IV Granted Priority Review
Pharmion's NDA supplement for IV administration of its demethylating agent Vidaza (azacitidine) has a Sept. 29 user fee date under a six-month review, the company announced June 13